This week in therapeutics

Indication	Target/marker/ pathway	Summary	Licensing status	Publication and contact information
Ophthalmic disease				
Retinal detachment	Mineralocorticoid receptor	<p>Rat and human studies suggest antagonizing the mineralocorticoid receptor could help treat central serous chorioretinopathy (CSCR). CSCR involves dilation and leakage of choroid vessels under the retina, which causes retinal detachment. In rats, intravitreal injection of the mineralocorticoid receptor activator aldosterone induced choroid vessel dilation and leakage. In two patients with chronic CSCR, the mineralocorticoid receptor antagonist eplerenone decreased subretinal fluid retention compared with that seen prior to treatment and resolved retinal detachment for up to five months following treatment withdrawal. Next steps include clinical testing and development of a new formulation of the compound. Pfizer Inc. markets Inspra eplerenone to treat hypertension and myocardial infarction (MI).</p> <p><i>SciBX</i> 5(27); doi:10.1038/scibx.2012.709 Published online July 12, 2012</p>	Patent application filed; available for licensing	<p>Zhao, M. <i>et al. J. Clin. Invest.</i>; published online June 11, 2012; doi:10.1172/JCI61427 Contact: Nicolette Farman, Institut National de la Santé et de la Recherche Médicale (INSERM) U872 Cordelier Research Center, Paris, France e-mail: nicolette.farman@crc.jussieu.fr</p>